Redcare Pharmacy stock (NL0012044747): Digital pharmacy leader eyes US expansion

Redcare Pharmacy, Europe's leading online pharmacy, reported strong Q1 growth amid rising telehealth demand. Shares gained 2.1% on Frankfurt. Key metrics and outlook for US investors.

Redcare Pharmacy (Shop Apoth), the Netherlands-based digital pharmacy pioneer, continues to capture market share in Europe's online health sector. The company announced first-quarter results on May 6, 2026, showing revenue up 18% year-over-year to €285 million for the period ending March 31, 2026, according to IR Redcare Pharmacy as of 05/06/2026. This performance drove shares up 2.1% to €285.50 on Xetra on May 7, 2026, per Boerse Frankfurt as of 05/07/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Redcare Pharmacy N.V.
• Sector/industry: Healthcare / Digital Pharmacy
• Headquarters/country: Amsterdam, Netherlands
• Core markets: Germany, Netherlands, expanding EU
• Key revenue drivers: Online prescriptions, OTC products, telehealth
• Home exchange/listing venue: Xetra (Frankfurt) (RDC)
• Trading currency: EUR

Redcare Pharmacy: core business model

Redcare Pharmacy operates as a fully digital pharmacy platform, delivering prescription and over-the-counter medications directly to customers across Europe. Founded in 2015, it leverages proprietary technology for automated prescription processing, partnering with local pharmacies for fulfillment while maintaining strict regulatory compliance. The model eliminates physical stores, reducing costs and enabling scalability. In 2025 full-year results published February 20, 2026, revenue reached €1.05 billion, up 22% from prior year, per company annual report as of 02/20/2026.

The core strength lies in its end-to-end digital chain: from online consultations via licensed doctors to same-day delivery in key markets like Germany, where it holds 15% of the online pharmacy segment as of Q1 2026 data.

Main revenue and product drivers for Redcare Pharmacy

Prescription drugs account for 65% of revenue, driven by chronic illness management and telehealth integrations. OTC products and wellness items contribute 25%, with emerging growth from subscription services for recurring meds. Q1 2026 saw prescription orders rise 20% to 2.8 million, reflecting higher customer retention at 85%, according to the earnings release.

Geographic expansion into Benelux and planned UK entry bolsters drivers, with Germany still 80% of sales. Partnerships with insurers enhance reimbursement rates, key for margins at 12.5% EBITDA in Q1 2026.

Industry trends and competitive position

The European digital pharmacy market is projected to grow at 25% CAGR through 2030, fueled by aging populations and post-pandemic telehealth adoption, per Statista as of 04/15/2026. Redcare Pharmacy leads with 25 million+ orders processed annually, ahead of rivals like DocMorris.

Its competitive edge includes proprietary AI for inventory and a doctor network of 500+, enabling faster fulfillment than traditional chains.

Why Redcare Pharmacy matters for US investors

US investors gain exposure to Europe's booming e-health sector via Redcare's Xetra listing, mirroring US trends at firms like Hims & Hers. With 20% of revenue tied to US pharma suppliers and potential FDA-aligned expansions, it offers diversification amid US regulatory shifts in telehealth.

Q1 2026 results in detail

Revenue hit €285 million (+18% YoY), gross margin improved to 28% from 26%, and adjusted EBITDA rose 25% to €35.5 million for January-March 2026. Active customers grew 30% to 1.2 million. Management reaffirmed 20%+ full-year growth guidance, citing strong demand.

Share price reaction and valuation

Post-earnings, shares rose 2.1% to €285.50 on May 7, 2026, on Xetra volume of 250,000 shares, per Boerse Frankfurt. YTD gain stands at 15%, trading at 4.5x 2026 EV/sales estimates.

Conclusion

Redcare Pharmacy demonstrates robust growth in the digital pharmacy space, with Q1 results underscoring execution amid favorable sector tailwinds. Expansion plans and margin gains position it well, though regulatory risks in new markets persist. US investors may track its EU leadership for global e-health insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.